Community Screening Study Using Polygene Methylation Testing for Colorectal Cancer in Yangzhou Residents Aged 40 to 74

What this Trial Is About

Researchers are conducting a large community-based observational study in Yangzhou to assess the effectiveness of a polygene methylation test in screening for colorectal cancer. This study aims to evaluate how well this test detects colorectal cancer and precancerous lesions in real-world settings by enrolling 80,000 permanent residents aged 40 to 74 years. The study will last five years and is jointly developed by Northern Jiangsu Peoples Hospital and Shanghai Kunyuan Biological Technology Co., LTD. At the start, participants will complete a colorectal cancer risk questionnaire and provide samples for the polygene methylation test. Those with positive test results will undergo further testing including a fecal immunochemistry test, blood carcinoembryonic antigen test, and colonoscopy within three months. These follow-up tests help confirm the presence of colorectal cancer or precancerous lesions. Participants will be followed by phone at 1, 2, 3, 4, and 5 years after the initial screening to collect medical history and survival outcomes. The study will use colonoscopy and pathology results to confirm diagnoses. Researchers will assess outcomes such as the sensitivity, specificity, and detection rates of the screening methods, with study endpoints reached when colorectal cancer or related lesions are diagnosed or treated.

A Community Population Screening Cohort Study Based on Polygene Methylation Detection for Colorectal Cancer in Yangzhou